About Dirk Beher

• CEO and founder of Asceneuron, visionary entrepreneur and patient-centric drug developer
• Long standing CNS drug discovery and development experience (>24 years in pharma/biotech)
• Key expertise in the science-driven stages of company creation, operations & development (Seed to Series B)
• Multiple molecules advanced from discovery into clinical development (most advanced molecule to Phase 2/3 IND in US); includes AU, EU, UK & US regulatory approvals and US ODD & EU OMPD
• >9 years of C-level and board experience as founding CEO, CSO and board director
• CHF 75M (USD 80M) raised from leading venture capital firms and prestigious research awards/grants (CHF 3M total)
• Inventor of 2 granted patents, 6 pending applications and author of >50 peer-reviewed publications and reviews (~6,000 citations on Google Scholar); invited speaker a leading research conferences

Specialties: Company & international subsidiary creation, corporate strategy, venture capital and non-dilutive fundraising, entrepreneurship, recruitment of executive management and board directors, R&D and line management, business development, deal negotiations, CNS drug discovery and development, neurodegenerative diseases, molecular pharmacology (GPCRs and enzymes), biochemistry, cell biology, target validation and concept generation, small molecules and biologics, translational biomarkers, amyloid-beta, tau protein, proteinopathies